Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01086345 · ClinicalTrials.gov registry record · Early Phase 1
Radiosurgery Plus Bevacizumab in Glioblastoma
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT01086345: Clinical Trial Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
NCT01086345 is a Early Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 9 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01086345, a Early Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of glioblastoma by blocking blood flow to the tumor. Drugs used in chemotherapy such as irinotecan hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiosurgery together with bevacizumab and irinotecan hydrochloride may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving radiosurgery together with bevacizumab and irinotecan hydrochloride works in treating patients with recurrent glioblastoma.
Interventions
- RADIATION radiosurgery
- BIOLOGICAL bevacizumab
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
Why NCT01086345 stopped before completion
NCT01086345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which radiosurgery is the first listed.
NCT01086345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01086345 about?
NCT01086345 is a clinical study titled "Radiosurgery Plus Bevacizumab in Glioblastoma". RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tu...
What is the current status of trial NCT01086345?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2010-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01086345?
The interventions under investigation include: radiosurgery (RADIATION), bevacizumab (BIOLOGICAL), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01086345?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01086345's enrollment target sits among peer trials
9 1745th of 2000 higher than 219 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia